ArticleRSC advances2026
Synthesis of withaferin a derivatives and exploratory evaluation of weight reduction and fasting blood glucose in DIO mice.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and its cardiometabolic complications remain a major public-health burden. Leptin resistance is a common feature of hyperleptinemic obesity, but the molecular basis of leptin resensitization remains incompletely understood, making the rational optimization of leptin-sensitizing agents difficult. Withaferin A (1) has been reported to enhance leptin responsiveness and to reduce body weight and the fasting blood glucose in diet-induced obese (DIO) mice. In this study, a series of withaferin A derivatives (2-15) bearing modifications in the A/B-ring region and the C-27 side-chain/lactone moiety was synthesized and evaluated in DIO mice. The compounds were administered intraperitoneally at 1.2 mg kg
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.